Skip to main content
The Markets by Proactive
Go to Proactive Australia

Archive

PetVivo Holdings CEO says its Spryng tech has now treated 1,000 animals for osteoarthritis

PetVivo Holdings CEO says its Spryng tech has now treated 1,000 animals for osteoarthritis

PetVivo Holdings (NASDAQ:PETV) Inc CEO John Lai tells Proactive the biomedical device company's Spryng technology, which aims to treated osteoarthritis in dogs and horses, has now treated 1,000 animals. Spryng is a veterinarian-administered, intra-articular injection designed to aid in the management of lameness issues, joint pain and osteoarthritis from loss of cartilage or tissue-bone mechanical malfunction caused by joint dysfunction.